ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Catalyst OrthoScience Announces Mark Quick as Chief Financial Officer

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has appointed seasoned medical device leader Mark Quick as chief financial officer of the organization, effective immediately.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230606005924/en/

Catalyst OrthoScience Announces Mark Quick as Chief Financial Officer (Photo: Business Wire)

Catalyst OrthoScience Announces Mark Quick as Chief Financial Officer (Photo: Business Wire)

Quick joins Catalyst with nearly two decades of medical device experience. He was most recently at Orthofix Medical Inc. where he served in financial leadership and business development roles of increasing responsibility across financial planning and analysis, investor relations, and mergers and acquisitions.

Prior to Orthofix, he served as a sell-side equity research analyst covering the medical device industry at Canaccord Genuity. Quick holds a Bachelor of Science in Mechanical Engineering from the University of Massachusetts, Amherst and an International Master of Business Administration from the University of South Carolina.

“I am thrilled to join Carl and the rest of the talented Catalyst team in their commitment, dedication, and focus to providing differentiated solutions to shoulder surgeons and patients,” said Quick. “With its growing product portfolio, Catalyst is positioned to accelerate expansion of its distribution channel leading to broad adoption in the high-growth $1.5 billion U.S. shoulder replacement market.”

Catalyst recently received 510(k) clearance from the FDA to market its fully convertible stemmed total shoulder arthroplasty system with an ellipsoid anatomic head. This is the market’s first stemmed arthroplasty system featuring an ellipsoid humeral head, and expands the Catalyst portfolio to offer stemless, stemmed, and convertible shoulder replacement systems.

“Mark brings a wealth of expertise in the medical device market to our team, and we are excited to leverage his decades of experience as we continue to grow,” said Carl O’Connell, CEO and president of Catalyst. “Our purposely designed approach to shoulder replacement surgery is focused squarely on solutions that better match the patient’s own anatomy, reduce complications and support the needs of surgeons for precision, accuracy and repeatability.”

About Catalyst OrthoScience Inc.

Naples, Florida-based Catalyst OrthoScience was founded in 2014 by orthopedic surgeon Steven Goldberg, MD, who saw the need to make shoulder replacements less invasive, with fewer complications and a more natural-feeling shoulder after surgery. Catalyst is disrupting the traditional approach to shoulder replacement surgery. Our total shoulder systems offer precision and accuracy in shoulder restoration while preserving the patient’s bone and soft tissue. Catalyst has a growing portfolio of patents and pending patents on its distinctive offerings, which are available across the U.S. For more information, visit www.catalystortho.com.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.28
+0.00 (0.00%)
AAPL  273.05
+0.00 (0.00%)
AMD  274.95
+0.00 (0.00%)
BAC  53.95
+0.00 (0.00%)
GOOG  335.40
+0.00 (0.00%)
META  670.91
+0.00 (0.00%)
MSFT  418.07
+0.00 (0.00%)
NVDA  202.06
+0.00 (0.00%)
ORCL  177.58
+0.00 (0.00%)
TSLA  392.50
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.